In this sense, in an animal model of progressive muscle weakness, such as Duchenne muscular dystrophy, Liang et al. [48] observed that cenicriviroc (CVC), a dual chemokine receptor (CCR2/CCR5) antagonist, could slow disease progression. The gene discussed is CCR5; the disease is Duchenne muscular dystrophy.